At scale, materials, particularly DNA and transfection reagents, represent a significant portion of total production cost. This is especially true for high-dose AAV therapies, where input requirements increase exponentially. Discover how switching DNA platforms can directly impact overall COG.
- Double-digit percentage reductions in COG - Significant annual cost savings at commercial scale
Discover Why DNA Inputs Are Driving AAV Manufacturing Costs Higher
Partners
Platform Technology Licenses
About Touchlight
At Touchlight, we’ve reimagined DNA production to meet the evolving needs of innovators like you. Our patented synthetic DNA vector, dbDNA™, and cell-free enzymatic manufacturing platform deliver DNA with unmatched speed, scale, and purity, helping you move faster from discovery to clinic.
World's First
GMP-Licensed Cell-Free DNA Facility
Touchlight operates the first GMP-licensed facility for producing synthetic DNA using a completely cell-free enzymatic process.
>1500
Batches
To date, Touchlight has produced over 1500 batches of cell-free DNA using its proprietary dbDNA™ platform.
Tripled
Manufacturing Capacity in 2024
Touchlight recently tripled its production capacity with a major expansion of its Morelands facility in London.
